🟢 Edesa Biotech is trading 5% up in pre-market after pricing a $25 million underwritten offering

Edesa Biotech is trading at $5.00 (+5.04%) after pricing a $25 million underwritten public offering on August 20, 2026.

• The financing includes 3.87 million shares, pre-funded warrants, and accompanying warrants exercisable at $7.50 per share.
• The offering is expected to close on August 21, 2026; proceeds will support working capital, research, development, manufacturing, and capital expenditures.
• The move follows a 17.22% decline on August 20, suggesting a rebound after the financing-related selloff.